BlackRock Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

BlackRock Investment Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.78M	Buy	58,095 +10,369	+22%	+$410K	﹤0.01%	1992
2016 Q3	$1.75M	Sell	47,726 -11,787	-20%	-$369K	﹤0.01%	2260
2016 Q2	$1.39M	Sell	59,513 -55,857	-48%	-$1.8M	﹤0.01%	2396
2016 Q1	$4.67M	Sell	115,370 -21,607	-16%	-$878K	0.01%	1425
2015 Q4	$8.48M	Buy	136,977 +20,601	+18%	+$1.11M	0.01%	1043
2015 Q3	$4.7M	Sell	116,376 -760	-0.6%	-$39.3K	0.01%	1428
2015 Q2	$6.74M	Sell	117,136 -287,486	-71%	-$18.3M	0.01%	1266
2015 Q1	$25.8M	Buy	404,622 +36,416	+10%	+$2.47M	0.03%	463
2014 Q4	$22.7M	Buy	368,206 +31,101	+9%	+$1.53M	0.03%	496
2014 Q3	$13.1M	Buy	337,105 +1,652	+0.5%	+$58.5K	0.02%	756
2014 Q2	$11.6M	Buy	335,453 +25,161	+8%	+$792K	0.02%	879
2014 Q1	$13.4M	Buy	310,292 +1,440	+0.5%	+$69.8K	0.02%	729
2013 Q4	$12.3M	Sell	308,852 -7,246	-2%	-$258K	0.02%	764
2013 Q3	$11.9M	Buy	316,098 +18,722	+6%	+$559K	0.02%	725
2013 Q2	$7.99M	Buy	+297,376	New	+$6.32M	0.01%	898

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's IONS Position: Q4 2016 in Review

BlackRock Investment Management increased its Ionis Pharmaceuticals (IONS) stake by 22% in Q4 2016, buying an estimated $410K and bringing the position to 58,095 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1992.

BlackRock Investment Management first reported a position in IONS in Q2 2013 and has held it in 15 quarters since. The position peaked at $25.8M in Q1 2015. 308 funds tracked by Wall St. Rank hold IONS as of Q4 2016.

BlackRock Investment Management held 58,095 shares of Ionis Pharmaceuticals worth $2.78M as of Q4 2016.
BlackRock Investment Management bought 10,369 Ionis Pharmaceuticals shares in Q4 2016, an estimated $410K.
Ionis Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1992 holding.
BlackRock Investment Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Ionis Pharmaceuticals position peaked at $25.8M in Q1 2015.
308 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.